ArticleFrontiers in neurology2025
Synergistic benefits of melatonin and therapeutic exercise as a unified strategy for managing stroke and doxorubicin-induced cardiotoxicity.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Epidemiological studies highlight a significant occurrence of ischemic strokes in cancer patients, particularly in the elderly, where stroke and systemic cancer are the leading causes of death. This comprehensive study investigates the combined effect of melatonin (MT) and exercise (Ex) against stroke, and a chemotherapeutic drug doxorubicin (Dox)-induced cardiotoxicity (DIC). Method: This study employs two models-middle cerebral artery occlusion (MCAo) and DIC-to evaluate the synergistic effects of MT + Ex. For both models, rats were assigned to the same treatment groups ( Results: In the MCAo model, the MT + Ex group showed a significant reduction in brain infarct volume and neurological deficits compared to control animals ( Conclusion: MT + Ex reduced brain infarct volume and neurological deficits, enhanced neuronal growth, and provided superior cardioprotection, preventing heart weight loss and histopathological damage. This study is the first to show synergistic protective action of MT and Ex against stroke and DIC, contributing key insights into an interplay between neurological and cardiovascular health and addressing multifaceted challenges posed by stroke, and anticancer interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.